Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Progressive Multifocal Leukoencephalopathy in Patients with a Hematological Malignancy: Review of Therapeutic Options

(2014) Alexander Kalisch et al.   CHEMOTHERAPY

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

(2014) R. C. Dale et al.   NEUROLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function

(2013) E. G. Kamburova et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies

(2013) Maria J Leandro   ARTHRITIS RESEARCH & THERAPY

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

(2013) Su-Hyun Kim et al.   JAMA Neurology

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

(2011) David B. Clifford   ARCHIVES OF NEUROLOGY

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

(2011) W. Rigby et al.   ARTHRITIS AND RHEUMATISM

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Response of patients with refractory myasthenia gravis to rituximab: a retrospective study

(2011) Richard J. Nowak et al.   Therapeutic Advances in Neurological Disorders

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Treatment of Neuromyelitis Optica With Rituximab

(2008)   ARCHIVES OF NEUROLOGY

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?

(2008) Eamonn S. Molloy et al.   AUTOIMMUNITY REVIEWS

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

B cells as therapeutic targets in autoimmune neurological disorders

(2008) Marinos C Dalakas   Nature clinical practice. Neurology